Similarly, future studies may indicate that pharmacological or genetic inhibition of transcriptional or translational expression of USP14 may constitute a therapeutic avenue leading to induction of cell death in GBM in vitro and in vivo. This evidence concerns the gene USP14 and glioblastoma.